Navigation Links
Vermillion Announces Notice of Issuance of U.S. Patent Covering Hepcidin as a Biomarker for Ovarian Cancer
Date:2/12/2009

- Discovery Could Lead to the Development of a Next-Generation Assay to Improve Diagnosis and Treatment of Ovarian Cancer -

FREMONT, Calif., Feb. 12 /PRNewswire-FirstCall/ -- Vermillion, Inc. (OTC Bulletin Board: VRML), a molecular diagnostics company, today announced that the U.S. Patent Office (USPTO) has issued a notice of allowance to the Company for the discovery of hepcidin as a biomarker for ovarian cancer. The discovery could ultimately lead to the development of an improved, next-generation assay that might provide physicians with additional, valuable information to diagnose ovarian cancer.

"The notice of issuance of this patent validates the strength of our approach in the development of innovative molecular diagnostics," said Eric T. Fung, M.D., Ph.D, Chief Scientific Officer of Vermillion and co-inventor. "This patent comprises an important component of our ovarian cancer patent portfolio."

The patent also covers the measurement of hepcidin by a variety of methods, including mass spectrometry and other immunoassay approaches.

About Vermillion's Ovarian Cancer Diagnostic Program

Vermillion has multiple ovarian cancer diagnostic tests in development. The most advanced of Vermillion's programs is the OVA1 test, which is designed to utilize a panel of biomarkers to help identify women with a higher likelihood of malignancy so they can be referred to a gynecologic oncologist for their initial surgery. Vermillion filed a 510(K) Application with the U.S. Food and Drug Administration for its OVA1(TM) Test in June 2008.

Additionally, studies are underway to develop tests with the capability of detecting early-stage ovarian cancer, predicting prognosis and recurrence, and identifying women considered at high-risk for the disease.

Vermillion's premier diagnostic development program is being conducted with several leading collaborators at T
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vermillion Announces Receipt of NASDAQ Panel Decision
2. Vermillion and Stanford Scientists Receive Best Research Award From the PAD Coalition
3. Vermillion Retains ThinkPanmure to Assist in the Evaluation of Potential Strategic Alternatives
4. Vermillion to Host Live Roundtable Discussion With Principal Investigator of OVA1(TM) Submission
5. Vermillion Announces First Quarter 2008 Financial Results and Business Progress
6. Vermillions Roundtable Teleconference Highlights Peripheral Artery Disease Diagnostic Program; Features Commentary from Vascular Medicine Expert
7. Vermillion Announces Appointment of John Hamilton to Board of Directors
8. Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Artery Disease
9. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
10. Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones
11. Vermillion Announces Effectiveness of Reverse Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 30, 2015 Sanofi, a ... the second quarter of 2015. CEO Olivier ... its performance in different businesses. Watch ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics covered in the ... - Performance drivers - Diabetes ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... , the Company,s Chief Financial Officer has resigned.  The ... Chief Financial Officer who retired in December 2014, as ... for a permanent successor.     Andy Ashworth ... Laurin and ensure a smooth transition.  Andy was the ...
(Date:7/29/2015)... Wis. (PRWEB) , ... July 29, 2015 , ... ... identification solutions, today announced its GHS Label Guide . To align chemical ... System (GHS), this guide includes explanations of label components, an example of an ...
(Date:7/29/2015)... ... ... The third Medical Innovation Impact Index (MI3) Alert considers FDA processes for the ... system received a score of 0 (range -10 to +10) for its impact on ... Dickinson University’s ( FDU ) Rothman Institute of Innovation and Entrepreneurship. Several changes to ...
Breaking Biology Technology:BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3Brady Announces a New GHS Label Guide 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3
... Mich., April 15 GeneGo, Inc., the leading,systems ... Science Institute has joined the MetaMiner Cardiac,Consortium. The ... first systems,biology and pathway analysis platform for cardiovascular ... on deliverables that will include,disease specific pathway maps ...
... April 15 WallSt.net,s 3-Minute Press Show is,a ... Tolentino., Shows air Monday through Friday on:, ... Show features in-depth interviews with,public company executives on ... is designed to provide viewers with insight into ...
... /PRNewswire-FirstCall/ - AEterna Zentaris Inc.,(NASDAQ: AEZS ; ... therapy and oncology, today reported the completion of ... its Phase 3 program,in benign prostatic hyperplasia (BPH), ... product candidate, cetrorelix. The study,involves approximately 600 patients ...
Cached Biology Technology:The Scripps Translational Science Institute Joins The MetaMiner Cardiac Consortium 2Featured Stocks on Today's Edition of WallSt.net's 3-Minute Press Show: NPHC, PECD, PNRR 2Featured Stocks on Today's Edition of WallSt.net's 3-Minute Press Show: NPHC, PECD, PNRR 3AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia 3AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia 4
(Date:7/8/2015)... LAKES , N.J. and NEW YORK ... Company) and Guidepoint today announced BD ... start-up healthcare companies with free access to Guidepoint,s expert ... several start-ups that are developing cutting-edge technologies to improve ... a dedicated Guidepoint research manager, each start-up entrepreneur will ...
(Date:7/7/2015)... Calif. , July 7, 2015  Based ... market, Frost & Sullivan recognizes Credence ID, LLC ... Entrepreneurial Company of the Year Award. Credence ... to aid in its mission of offering enrollment ... populations globally. As Credence ID was formed by ...
(Date:7/2/2015)... Fingerprint Cards has received an order for its ... distributor World Peace Industrial Group (WPI), part of WPG Holdings. ... . Deliveries are planned to take place during Q3 ... manufacturers in Asia . The order value ... of approximately 2,200 MSEK for 2015. Jörgen Lantto, ...
Breaking Biology News(10 mins):BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2
... Conservancy (WPC) scientists have discovered a plant in Erie County ... dwarf scouring rush, was identified with the aid of a ... Girard. Dwarf scouring rush is known to exist in ... not been identified in Pennsylvania until this discovery. WPC scientists ...
... The Potato Genome Sequencing Consortium (PGSC), an international ... countries, has released a draft sequence of the potato ... Richard Veilleux, professor of horticulture in the College ... a unique phureja type of potato variety that accelerated ...
... Investigators at Burnham Institute for Medical Research (Burnham), University ... Research Institute (TSRI), Genomics Institute of the Novartis Research ... model, including three dimensional protein structures, of the central ... ( T. maritima ). This is the first time ...
Cached Biology News:Erie County home to plant never before recorded in Pa. 2Draft potato genome based on unique potato variety 2Comprehensive understanding of bacteria could lead to new insights into many organisms 2
Best pricing for 100mg-1.0g scales. Phosphopeptides are our specialty....
... The ProteomeLab PF 2D is an automated, ... complex protein mixtures. Part of Beckman ... 2D produces results in just hours. ... proteins present in cell lysates, addressing a ...
... Panels were designed for full-length gene cloning ... to identify the desired cDNA clone. The ... 96-well "Master Plate," where each well contains ... the positive well(s) by gel electrophoresis of ...
... 295 ex can measure three fluorescence lifetimespicoseconds ... a few minutes. To match the absorption ... tryptophan, the Protein 295 exs excitation source ... emitting 295 nm. Fluorescence of tryptophan is ...
Biology Products: